Skip to main
  1. Stocks
  2. ICON
  3. Forecast
ICLR

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 38%
Hold 31%
Sell 8%
Strong Sell 0%

Bulls say

Icon is positively viewed because strong bookings, including B2B above 1.2x for four consecutive quarters and 1.3x TTM direct-fee B2B, suggest revenue visibility well into 2027 even if growth moderates from recent peaks. Execution has improved across large pharma, biotech, FSO, FSP, labs, and evidence generation, while AI-enabled workflow gains are reducing cycle times and supporting margin expansion, with gross margin up 90 bps sequentially and EBITDA margin up to 16.6%. The business also has balance-sheet strength and capital returns, generating $302 million of free cash flow in 3Q and repurchasing $400 million of stock, while industry tailwinds like improving biotech funding, rising INDs, and near-COVID clinical trial starts support durable demand.

Bears say

Icon is exposed to a CRO market that can weaken if government regulation, macroeconomic softness, or biopharma consolidation reduces sponsors’ willingness and ability to fund outsourced research. The downside case already assumes only low-single-digit top-line growth and EBITDA margin degradation in 2027, with valuation anchored at 11.0x the downside EBITDA estimate and peer minimum 3-year multiples. Further accounting reviews, backlog reductions, delayed trials from slower patient enrollment or site selection, and talent-driven wage inflation could pressure confidence, bookings, margins, and the company’s reputation.

ICON (ICLR) has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 38% recommend Buy, 31% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

ICON (ICLR) Analyst Forecast & Price Prediction

Get the latest ICON (ICLR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ICON (ICLR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 13 analysts, ICON (ICLR) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $205.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $205.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


ICON (ICLR) Analyst Forecast & Price Prediction

Get the latest ICON (ICLR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ICON (ICLR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ICLR stock data and trends